TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
The treatment of acute leukemias remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which approach is most appropriate requires careful consideration of patient and disease characteristics, physician expertise and available health-system resources. Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms. In order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances.

To bridge the gap between research and patient care, this issue of Acute Leukemias Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this CME activity will assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies.

LEARNING OBJECTIVES

• Appraise current data on recent therapeutic advances and changing practice standards, including FDA approvals, in acute forms of leukemia, and integrate this information into clinical care.
• Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to refine diagnostic algorithms for acute myeloid leukemia (AML).
• Consider patient- and disease-related factors in the selection and sequencing of therapy for AML.
• Recall the early efficacy and toxicity data with the use of chimeric antigen receptor T-cell therapy, bispecific T-cell engagers and antibody-drug conjugates for patients with relapsed acute lymphoblastic leukemia, and where appropriate, facilitate patient access to this approach.
• Identify the mechanisms of action, efficacy and side effects of newly approved and investigational agents demonstrating promising activity in acute forms of leukemia, and refer appropriate patients for clinical trials evaluating these approaches.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: 

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Member, Leukemia Program
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Agios Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, NewLink Genetics Corporation, Takeda Oncology; Consulting Agreements: AbbVie Inc, Arog Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc; Contracted Research: Actinium Pharmaceuticals Inc, Astellas, Bayer HealthCare Pharmaceuticals, BioMed Valley Discoveries Inc, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Novartis; Data and Safety Monitoring Board: Leukemia & Lymphoma Society, Takeda Oncology.

Eunice Wang, MD
Chief, Leukemia Service
Professor of Oncology
Director, Hematologic Procurement Shared Resource
Department of Tumor Immunology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, Astellas, Celyad, Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Pfizer Inc, Stemline Therapeutics Inc; Data and Safety Monitoring Board: AbbVie Inc, Bristol-Myers Squibb Company, Rafael Pharmaceuticals Inc; Site Investigator for Clinical Trials: Amgen Inc, Aptevo Therapeutics, Arog Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, FUJIFILM Pharmaceuticals USA Inc, ImmunoGen Inc, Incyte Corporation, Kura Oncology, Takeda Oncology, Tolero Pharmaceuticals, Stemline Therapeutics Inc, Trovagene; Speakers Bureau: Pfizer Inc, Stemline Therapeutics Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Astellas, Celgene Corporation, Jazz Pharmaceuticals Inc and Pfizer Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: February 2020
Expiration date: February 2021